1. Home
  2. BNC vs BCDA Comparison

BNC vs BCDA Comparison

Compare BNC & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNC
  • BCDA
  • Stock Information
  • Founded
  • BNC N/A
  • BCDA N/A
  • Country
  • BNC United States
  • BCDA United States
  • Employees
  • BNC N/A
  • BCDA N/A
  • Industry
  • BNC Industrial Machinery/Components
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BNC Industrials
  • BCDA Health Care
  • Exchange
  • BNC Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • BNC 13.7M
  • BCDA 11.3M
  • IPO Year
  • BNC N/A
  • BCDA N/A
  • Fundamental
  • Price
  • BNC $17.07
  • BCDA $2.01
  • Analyst Decision
  • BNC
  • BCDA Strong Buy
  • Analyst Count
  • BNC 0
  • BCDA 1
  • Target Price
  • BNC N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • BNC 343.8K
  • BCDA 65.7K
  • Earning Date
  • BNC 09-16-2025
  • BCDA 08-11-2025
  • Dividend Yield
  • BNC N/A
  • BCDA N/A
  • EPS Growth
  • BNC N/A
  • BCDA N/A
  • EPS
  • BNC N/A
  • BCDA N/A
  • Revenue
  • BNC $3,478,254.00
  • BCDA N/A
  • Revenue This Year
  • BNC N/A
  • BCDA N/A
  • Revenue Next Year
  • BNC N/A
  • BCDA N/A
  • P/E Ratio
  • BNC N/A
  • BCDA N/A
  • Revenue Growth
  • BNC 10.08
  • BCDA N/A
  • 52 Week Low
  • BNC $5.60
  • BCDA $1.63
  • 52 Week High
  • BNC $82.88
  • BCDA $3.26
  • Technical
  • Relative Strength Index (RSI)
  • BNC N/A
  • BCDA 52.98
  • Support Level
  • BNC N/A
  • BCDA $1.90
  • Resistance Level
  • BNC N/A
  • BCDA $1.99
  • Average True Range (ATR)
  • BNC 0.00
  • BCDA 0.08
  • MACD
  • BNC 0.00
  • BCDA 0.03
  • Stochastic Oscillator
  • BNC 0.00
  • BCDA 83.59

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: